The pharmacy services sector saw substantial M&A activity between June 2025 and May 2026, as private equity firms continued to drive consolidation across specialty pharmacy, infusion services, compounding, and pharma services platforms. This activity reflects a strategic shift toward scale, efficiency, and specialization as organizations respond to rising drug costs and evolving U.S. care models. In the U.S., drug spending increased by 11.4%. Looking ahead, specialty therapies—including oncology, autoimmune treatments, and metabolic drugs—are expected to drive renewed increases in drug spending through 2026–2027, even as overall trends temporarily moderate.
Regulatory Pressure & Margin Compression
Pharmacies continue to operate in a challenging regulatory and reimbursement environment. The 340B Drug Pricing Program remains a central source of uncertainty, with ongoing litigation and policy ambiguity affecting revenue predictability—particularly for specialty pharmacies that rely on discounted drug margins.
At the same time, pharmacy benefit managers (PBMs) and payers are intensifying scrutiny of specialty drug costs. Combined with increasing operational complexity—such as cold-chain logistics and biologics distribution—these pressures are compressing margins and forcing providers and pharmacy operators to reevaluate their cost structures and partnerships.
Consolidation & Targeted Acquisition Strategies
To navigate these headwinds, large pharmacy chains and integrated healthcare organizations are pursuing targeted M&A strategies that prioritize high-value assets.
Rather than acquiring entire organizations, buyers are focusing on large-scale restructurings, selective “files and stores” asset acquisitions, bolt-on transactions to existing platforms, and acquisitions that expand control across the pharmaceutical value chain through vertical integration.
CVS Health’s acquisition of 63 Rite Aid store locations and more than 600 pharmacy prescription files across 15 states exemplifies the “files and stores” approach. The transaction enabled CVS to expand prescription volume and geographic reach, while limiting its exposure to underperforming assets. In parallel, the broader restructuring of Rite Aid—including its bankruptcy and asset liquidation—highlights the increasing pressure on smaller operators who lack scale.
Walgreens Boots Alliance offers another example of industry repositioning. Its take-private transaction in August 2025 reflects a growing trend toward large-scale restructuring to improve fundamentals, allowing organizations to focus on operational improvements and long-term strategic flexibility outside the public market environment.
Vertical Integration & Market Concentration
Vertical integration continues to reshape the pharmacy landscape, with significant implications for providers. CVS Health, OptumRx, and Express Scripts (Cigna) now collectively manage pharmacy benefits for more than 75% of Americans. Payers and PBM-aligned entities view ownership of specialty dispensing capabilities as strategically critical to managing drug spend and retaining members.
Strategic investments further reinforce this model. Cigna’s Evernorth Health Services’ $3.5B investment in Shields Health Solutions expanded its specialty pharmacy capabilities and strengthened its ability to partner with providers and patients across care settings.
Shifting Sites of Care & Clinical Implications
Another defining trend is the migration of infusion and specialty pharmacy services to lower-cost sites of care, including outpatient clinics and home-based settings. This shift is creating measurable cost efficiencies while improving access to complex therapies.
While hospitals still administer nearly 40% of infusions, freestanding ambulatory infusion centers are on track to overtake hospital outpatient infusion volume by 2029, with a 30%–40% cost advantage and an annual growth rate of 12.54% Overall pharmacy spending is expected to increase by roughly 8.8% annually from 2025–2035 , underscoring the sustained demand for specialty services.
Looking Ahead
The pharmacy sector remains at a critical inflection point. Industry projections indicate that EBITDA across the pharmaceutical value chain could reach approximately $114B by 2029. M&A activity is expected to continue to strengthen through 2026 as private capital seeks deployment and a backlog of high-quality assets enters the market. Furthermore, platform physician practices with a specialty focus have begun considering vertical integration strategies, further driving M&A interest in the sector.
For healthcare leaders, success will depend on the ability to navigate regulatory complexity, respond to pricing pressures, and leverage strategic partnerships. Organizations that adapt to these structural shifts—while maintaining a clear focus on patient outcomes—will be best positioned to succeed in an evolving healthcare landscape.
As pharmacy services continue to consolidate and evolve, understanding market dynamics is critical to making informed strategic decisions. Connect with our team to better understand how these market changes may affect your organization’s future positioning.
